Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 106Fallopian Tube Neoplasms 48Carcinoma, Ovarian Epithelial 31Uterine Cervical Neoplasms 28Pancreatic Neoplasms 13Endometrial Neoplasms 13Neoplasms 10Colorectal Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 10Recurrence 7Prostatic Neoplasms 7Neoplasm Metastasis 7Lung Neoplasms 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Sarcoma 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Peritoneal Neoplasms 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4Melanoma 4Head and Neck Neoplasms 4Esophageal Neoplasms 4Colonic Neoplasms 4Vulvar Neoplasms 3Uterine Neoplasms 3Multiple Myeloma 3Carcinoma 3

Interventions

Taxes 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1CTLA-4 Antigen 1Bevacizumab 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Mucinous × Gemcitabine × Gynecologic × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡